替尔泊肽与甘精胰岛素对基于胱抑素C的肾功能的影响:SURPASS-4事后分析
SURPASS-4事后分析比较替尔泊肽(5、10、15 mg合并)与滴定甘精胰岛素对2型糖尿病高心血管风险成人eGFR的影响;52周时替尔泊肽组eGFR-肌酐和eGFR-胱抑素C下降幅度均小于胰岛素组,组间差异分别为1.4和1.8 mL/min/1.73 m²,eGFR变化与体重变化不相关。
要点
- 52周eGFR-肌酐变化:替尔泊肽组-2.5 vs 胰岛素组-3.9,组间差异1.4(95%CI 0.3-2.4)。
- 52周eGFR-胱抑素C变化:替尔泊肽组-3.5 vs 胰岛素组-5.3,组间差异1.8(95%CI 0.8-2.8)。
- eGFR变化与体重变化不相关,替尔泊肽延缓eGFR下降速度。
核心结论
- 替尔泊肽延缓eGFR下降速度,支持肾脏保护效应。
研究设计与样本
- SURPASS-4事后分析,对象为2型糖尿病且高心血管风险的成人,比较替尔泊肽(5、10、15 mg合并)与滴定甘精胰岛素。
- 主要结局为52周时eGFR较基线的变化。
主要发现
- eGFR-肌酐最小二乘均值(SE)变化:替尔泊肽组-2.5(0.38)vs 甘精胰岛素组-3.9(0.38),组间差异1.4(95%CI 0.3-2.4)。
- eGFR-胱抑素C最小二乘均值(SE)变化:替尔泊肽组-3.5(0.37)vs 甘精胰岛素组-5.3(0.37),组间差异1.8(95%CI 0.8-2.8)。
- eGFR-胱抑素C与eGFR-肌酐的基线值、1年值及1年较基线变化值均显著相关。
- eGFR变化指标与体重变化不相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Tirzepatide reduces HbA1c and body weight, and creatinine-based estimated glomerular filtration rate (eGFR) decline. Unlike creatine-derived eGFR (eGFR-creatinine), cystatin C-derived eGFR (eGFR-cystatin C) is unaffected by muscle mass changes. We assessed effects of tirzepatide on eGFR-creatinine and eGFR-cystatin C. RESEARCH DESIGN AND METHODS: Our primary outcome was eGFR change from baseline at 52 weeks with pooled tirzepatide (5, 10, and 15 mg) and titrated insulin glargine in adults with type 2 diabetes and high cardiovascular risk (SURPASS-4). RESULTS: Least squares mean (SE) eGFR-creatinine (mL/min/1.73 m2) changes from baseline with tirzepatide and insulin glargine were -2.5 (0.38) and -3.9 (0.38) (between-group difference, 1.4 [95% CI 0.3-2.4]) and -3.5 (0.37) and -5.3 (0.37) (between-group difference, 1.8 [95% CI 0.8-2.8]) for eGFR-cystatin C. Baseline, 1-year, and 1-year change from baseline values significantly correlated between eGFR-cystatin C and eGFR-creatinine. Measures of eGFR changes did not correlate with body weight changes. CONCLUSIONS: Tirzepatide slows the eGFR decline rate, supporting a kidney-protective effect.
引用
- Heerspink HJL, Sattar N, Pavo I, et al. Effects of Tirzepatide Versus Insulin Glargine on Cystatin C-Based Kidney Function: A SURPASS-4 Post Hoc Analysis. Diabetes Care. 2023. PMID: 37267479. doi:10.2337/dc23-0261
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。